Skip to main content

Table 4 Hip size: effectiveness of treatments

From: The use of LeptiCore® in reducing fat gain and managing weight loss in patients with metabolic syndrome

 

Hip circumference (mean cm)

Hip change (%)

 

Initial

8 Weeks

8 Weeks - Initial

Formula B (↑dose)

123.38 ± 10.84

117.75 ± 17.24a

-4.56‡

Formula A (↓dose)

126.20 ± 12.91

121.80 ± 15.41a

-3.49†

Placebo

125.85 ± 14.72

125.45 ± 17.99

-0.32

  1. ap < 0.05; bp < 0.001 compared with Placebo
  2. *p < 0.05; **p < 0.001 compared with Formula A
  3. †p < 0.05; ‡p < 0.001 compared with Initial; intragroup analysis
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X